A Shanghai-based nicotinamide mononucleotide (NMN) ingredient firm is hopeful of NMN’s application and business opportunities in the US, despite recent news of the USFDA retracting its status as a New Dietary Ingredient (NDI).
The US Food and Drug Administration has issued an import alert and seized products from two firms that were deemed to be offering New Dietary Ingredients that have not gone through the notification process.
